Advertisement

---

VANDA PHARMACEUTICALS INC.

Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder

[2013-06-17] - Data presented at ENDO 2013, the Endocrine Society's 95th Annual Meeting


Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder

[2013-06-05] - Data presented as a late breaking abstract at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies


Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind

[2013-05-31] -


Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference

[2013-05-31] - Presentation will be Webcast Live and Archived on Vanda's Website


Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings

[2013-05-30] - -- Data to be presented at SLEEP 2013 27th Annual Meeting of the Associated Professional Sleep Societies and the Endocrine Society's 95th Annual Meeting


Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland

[2013-05-23] -


Vanda Pharmaceuticals Reports First Quarter 2013 Results

[2013-05-09] -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers